The regulation of G0-S transition in mouse T lymphocytes by polyamines.
While the role of polyamines in DNA synthesis during the S phase of the cell cycle has been repeatedly postulated, recent studies point also to polyamine involvement in the early phase of the G0-S transition. In order to determine polyamine-dependent steps in the cell cycle we have studied the effects of inhibitors of polyamine biosynthesis and exogenous polyamines on the proliferation of T lymphocytes as well as on the expression of some growth-regulated genes. The ability of Con A-stimulated mouse T lymphocytes to enter DNA synthesis was markedly inhibited by methylglyoxal bis(guanylhydrazone) in a dose-dependent manner. This inhibitory effect was stronger in the presence of fetal calf serum containing a high level of activities of polyamine oxidases than in the presence of horse serum. Putrescine and spermine added to T splenocyte culture instead of mitogen-Con A stimulated [3H]thymidine incorporation with kinetics similar to that observed with Con A. The growth-stimulating effects of polyamines were concentration-dependent. Polyamines at optimal growth-stimulating concentrations (10 microM spermine and 80 microM putrescine) induced the expression of genes encoding the cytoskeletal proteins beta-actin, vimentin, and alpha-tubulin to an extent and with kinetics similar to those of Con A. The results presented herein suggest that polyamines are capable of stimulating the transition of G0 cells to the S phase and that this effect may be mediated by their influence on the gene expression.
Kamińska
B
B
Department of Cellular Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland.
Kaczmarek
L
L
Grzelakowska-Sztabert
B
B
D000818:Animals; D002453:Cell Cycle / Q000187:drug effects* / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002462:Cell Membrane / Q000378:metabolism / Q000502:physiology / Q000648:ultrastructure; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D003598:Cytoskeletal Proteins / Q000235:genetics / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D051379:Mice; D008934:Mitogens / Q000494:pharmacology; D008935:Mitoguazone / Q000031:analogs & derivatives / Q000494:pharmacology; D011073:Polyamines / Q000378:metabolism / Q000494:pharmacology*; D011700:Putrescine / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016192:Resting Phase, Cell Cycle / Q000187:drug effects* / Q000502:physiology; D016196:S Phase / Q000187:drug effects* / Q000502:physiology; D011436:Spermidine Synthase / Q000037:antagonists & inhibitors; D013096:Spermine / Q000494:pharmacology; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D013601:T-Lymphocytes / Q000166:cytology* / Q000187:drug effects / Q000502:physiology
D003598:Cytoskeletal Proteins; D008934:Mitogens; D011073:Polyamines; D012333:RNA, Messenger; D003208:Concanavalin A; C054653:methylglyoxal bis(cyclohexylamidinohydrazone); D013096:Spermine; D004247:DNA; D011436:Spermidine Synthase; D008935:Mitoguazone; D011700:Putrescine